Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Novartis Scores With Orphan Drug

by Rick Mullin
August 26, 2013 | A version of this story appeared in Volume 91, Issue 34

FDA has approved Novartis’ BYM338 (bimagrumab), an antibody therapy for sporadic inclusion body myositis (sIBM), a rare muscle-wasting disease. Novartis codeveloped the therapy with MorphoSys. Bimagrumab is a fully human monoclonal antibody that binds with high affinity to type II activin receptors, stimulating muscle growth by blocking signaling from inhibitory molecules such as myostatin and activin. “With no effective therapies currently available for sIBM, bimagrumab has the potential to be the first real option for patients with this condition,” says Timothy Wright, Novartis’ head of pharmaceutical development.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.